Novel Drug Delivery Systems In Cancer Therapy Market Size, Share & Trends Analysis Report By Product (Nanoparticles, Embolization Particles), By Region, And by Segment Forecasts, 2024-2031

The Novel Drug Delivery Systems In Cancer Therapy Market Size is valued at USD 12.71 Billion in 2023 and is predicted to reach USD 63.25 Billion by the year 2031 at a 22.41 % CAGR during the forecast period for 2024-2031.

Key Industry Insights & Findings from the Report:

• The ability of novel drug delivery systems to deliver targeted therapies provides opportunities for personalized medicine.
• Advances in targeted therapies, including precision medicine and personalized treatment approaches, drive the demand for drug delivery systems that can precisely deliver therapeutic agents to specific cancer cells while sparing healthy tissues.
• North America dominated the market and accounted for a revenue share of global revenue in 2023.
• Issues related to scalability, manufacturing, and market acceptance can limit the commercialization of innovative technologies.

High-end drug delivery methods include expressing plant and bioactive extracts in microcapsules, liposomes, nano emulsions, nano capsules, hydrogels, microspheres, nanoparticles, and polymeric materials. Due to significant advantages over conventional medicines for cancer treatment, the market for novel drug delivery systems in cancer therapy is expected to grow. An increase in cancer occurrences significantly impacts the global market for novel drug delivery systems in cancer therapy. Additionally, there has been increased research activity to create novel drug delivery systems and increased financing for ongoing research initiatives.

The increase in the cost of healthcare for the detection and treatment of cancer is projected to contribute further to the expansion of the global market for novel drug delivery systems in cancer. Thus, with fresh investments and developments in the field, the high and rising burden of chronic diseases is anticipated to pave the way for developing novel drug delivery systems, and the studied market is thus expected to expand throughout the forecast period. Furthermore, the demand for novel drug delivery systems in cancer therapy is anticipated to increase due to technological developments in drug delivery systems, new investments made by private and public entities, new product launches, partnerships, and mergers and acquisitions by leading market players.

Market Segmentation:

The novel drug delivery systems in the cancer therapy market are segmented based on product. Based on the product, the market is segmented into nanoparticles (liposomes, polymer, micelles, other nanoparticles) and embolization particles (PVA particles, drug-eluting beads, liquid emboli, and other embolization particles).

Based On The Product, The Nanoparticles Segment Is A Significant Contributor To The Novel Drug Delivery Systems In The Cancer Therapy Market.

The nanoparticles segment is estimated to hold the largest share of the market. An innovative strategy for treating cancer uses nanoparticles as new drug delivery mechanisms. They enclose the medications and guard them against enzymatic and chemical deterioration. Long circulation half-lives, fewer adverse effects, and improved pharmacokinetics are all benefits of using nanoparticles in medication administration. Additionally, these particles have improved permeability, enabling effective medication delivery to cancer tissues.

In The Region, The North American Novel Drug Delivery Systems In The Cancer Therapy Market Hold A Significant Revenue Share.

North America region is projected to hold the largest share in the market of novel drug delivery systems in cancer therapy globally. The market is projected that the existence of various manufacturers and the availability of research funding will promote market expansion in North America or future developments in the global market for novel drug delivery systems in cancer therapy.  The Asia Pacific regional market is expected to increase rapidly in the global novel drug delivery systems in cancer therapy due to the invention and introduction of technologically sophisticated drug delivery systems. Furthermore, the growing patient population with chronic diseases is predicted to propel market growth.

Competitive Landscape

Some major key players in the Novel Drug Delivery Systems In Cancer Therapy Market:

• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson Services, Inc.
• GALEN
• Merrimack Pharmaceuticals, Inc.
• Shire
• Samyang Biopharmaceuticals Corporation
• Celgene Corporation
• Spectrum Pharmaceuticals, Inc.
• Other Market players

Novel Drug Delivery Systems In Cancer Therapy Market Report Scope

Segmentation Of Novel Drug Delivery Systems In Cancer Therapy Market

By Product

• Nanoparticles
  • Liposomes
  • Polymer
  • Micelles
  • Other nanoparticles
• Embolization particles
  • PVA particles
  • Drug-eluting beads
  • Liquid emboli
  • Other Embolization particles

By Region-

North America-

• The US
• Canada
• Mexico

Europe-

• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific-

• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific

Latin America-

• Brazil
• Argentina
• Rest of Latin America

 Middle East & Africa-

• GCC Countries
• South Africa

Rest of Middle East and Africa